Skip to main content

Table 1 Demographic and clinical characteristics at AAP initiation (baseline)

From: Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Variable

All patients (N = 481)

Age (years)

 Median (IQR)

75.0 (69.0–81.0)

 <  65, N (%)

53 (11.0)

 65–74, N (%)

168 (34.9)

 ≥ 75, N (%)

260 (54.1)

Comorbidities, N (%)a

 No comorbidities reported

152 (31.6)

 At least one comorbidity reported

329 (68.4)

  Any Cardiovascular event

281 (58.4)

   Hypertension

214 (44.5)

   Angina pectoris

27 (5.6)

   Myocardial infarction

24 (5.0)

   Arrhythmia

45 (9.4)

  Cerebrovascular accident

12 (2.5)

  Transient ischemic attack

8 (1.7)

  Other cardiovascular event

59 (12.3)

  Thromboembolic disease

10 (2.1)

  Any renal disorders

52 (10.8)

  Diabetes mellitusb

71 (14.8)

ECOG performance status, N (%)

 Unknown

202 (42.0)

 0

110 (22.9)

 1

134 (27.9)

 2

31 (6.4)

 3–4

4 (0.8)

Gleason score at initial prostate cancer diagnosis, N (%)

 Unknown

46 (9.6)

 ≤ 7

204 (42.4)

 ≥ 8

231 (48.0)

Laboratory parameters, median (IQR)

 PSA (ng/mL, N = 456)

56.2 (22.2–133.1)

 Alkaline phosphatase (units/L, N = 357)

119.0 (81.0–231.0)

 Lactate dehydrogenase (units/L, N = 184)

277.0 (197.5–382.5)

 Hemoglobin (g/dL, N = 375)

12.5 (10.8–13.8)

Location of metastases, N (%)

 Bone and/or lymph node metastases

429 (89.2)

  • Bone

378 (78.3)

  • Non-regional lymph node/s

63 (13.1)

  • Reginal lymph node/s

201 (41.8)

 Visceral (non-nodal soft tissue)

36 (7.5)

 Non-categorised

16 (3.3)

  1. aList of individual comorbidities is not mutually exclusive (same patient may have had two or more comorbidties). bIncludes insulin-dependent and non-insulin dependent. Abbreviations: ECOG Eastern Cooperative Oncology Group, IQR interquartile range, PSA prostate-specific antigen